Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.

J Hematol Oncol · 2022 · PMC9420297 · PMID 36031601

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

Regarding newer iterations, interim data released from a phase I trial involving uliledlimab in combination with atezolizumab (anti-PD-L1) in the management of advanced solid tumors reported an ORR of 23% (3/13) with a DCR of 46% (6/13), and a significant trend toward increased CD73 expression among treatment responders compared to non-responders (78% vs. 23%) [ 279 ].

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.